Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAD011 is a pharmaceutical-grade synthetic cannabidiol (CBD) oral solution developed for the treatment of hyperphagia and related neuro-behavioral symptoms in Prader-Willi syndrome (PWS). It is manufactured using traditional pharmaceutical processes to ensure high purity and consistency. The drug is being investigated for its potential to reduce excessive appetite and improve irritability and overall behaviors in PWS patients. RAD011 has been assessed in over 150 patients across multiple indications and has potential utility in other neuro-endocrine or metabolic orphan diseases[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RAD011.